Why Hire a CMC Consultant? The Case from Small Biotech to Large Pharma

CMC is where science meets regulatory reality, and it is the function most likely to be under-resourced in a small biotech and over-committed in a large one. In both cases, an experienced consultant solves a structural problem rather than a staffing gap and the problem is different depending on which end of the spectrum you're on.

The small biotech case: senior judgment without a senior headcount

A twelve-person company with a promising molecule rarely has the budget for a full-time VP of CMC, and often should not have one. What it needs is a handful of decisions made correctly at specific moments, and those decisions have a long half-life.

Specifications set too early are expensive to unset. Provisional acceptance criteria written before understanding your product's variability tend to get locked into an IND and need to be defended for years. Widening a specification after the fact requires justification you may not have generated. Getting the initial ranges right, wide enough to accommodate real manufacturing variability yet tight enough that reviewers see control, is a judgment call built on having watched many programs go through it.

Sequencing is where timelines get delayed. Programs rarely slip because a single assay failed. They slip because method qualification was not started early enough to support GMP release, because the reference standard was not qualified before the lot that needed it, or because two vendors were each waiting on the other. Someone who has run the sequence before can see the potential collisions months in advance and steer the company to avoid them.

Diligence readiness compounds. Partnering conversations and Series B diligence both look hard at the CMC package. A clean, defensible analytical strategy signals operational maturity in a way that preclinical data does not. The inverse is also true. A thin CMC section invites questions about everything else.

The economics are straightforward. A fractional senior resource, engaged on defined deliverables, costs a fraction of the fully loaded expense of a hire you may not need in eighteen months, and starts contributing immediately rather than after a search and a ramp.

CRO and CDMO oversight is where the return is highest

When your manufacturing, analytical development and stability program all live at external sites, your leverage comes entirely from the quality of your technical oversight.

You own the control strategy, not your CDMO. They will execute methods competently and hand you data. They will not decide which attributes are critical for your molecule, how your reference standard program should be structured, or whether the analytical package is coherent across drug substance and drug product. Sponsors who delegate that thinking tend to discover the gap during an information request. That is an expensive place to discover it.

Effective oversight means reading the raw data and not just the summary report, knowing which method transfer acceptance criteria are real and which are decorative, recognizing when an OOS investigation has been closed too neatly, and being able to have a technical conversation with the CDMO's scientists as a peer rather than as a customer. That skill set is hard to hire into a small company and it is what an experienced external lead brings on day one.

The large pharma case: capacity, objectivity, and the modality you have not built yet

Large organizations have deep CMC benches but they still hire consultants.

Surge capacity around filings. Module 3 authoring, comparability packages and information request responses arrive in concentrated bursts. Hiring against a peak that lasts six months is inefficient. Borrowing capacity for exactly that window is not.

Modality-specific depth. A team that has characterized monoclonals for fifteen years is not automatically prepared for an ADC, a bispecific or a gene therapy vector. The analytical questions differ in ways that matter: DAR distribution and free payload for conjugates, chain pairing and mispairing for bispecifics, vector identity and empty to full ratios for AAV. Bringing in someone who has already made the mistakes on that modality is faster than making them internally.

Due diligence on in-licensed assets. Evaluating someone else's CMC package under time pressure is a distinct skill. What was actually qualified versus claimed as qualified, which commitments are embedded in the IND, how much rework the analytical package needs before it can support a BLA. Those are the findings that move valuation and the ones internal teams have the least bandwidth to chase.

Continuity through reorganization. When a program changes hands during a restructuring, institutional knowledge walks out the door. Someone who has been continuously engaged with the technical history is sometimes the only remaining memory of why a decision was made.

You are buying pattern recognition, not hours

The thing that makes CMC expensive to learn is that the lessons are spaced years apart. A scientist inside one company might see two INDs and, if they are lucky and the program survives, one BLA over a decade. That is a small sample from which to build judgment about what a reviewer will question, which comparability exercise will trigger a request for more data, or which specification you will regret setting at Phase 1.

Working across companies compresses that timeline. I have watched the same failure modes show up in molecule after molecule: a sequence variant that was ignored until the BLA, a CQA assessment that was written for the IND and never revisited, comparability plans built after the process change instead of before it. None of these are exotic problems. They are just expensive to discover in late stage.

That is the actual product. Not availability, not bandwidth. Judgment that was paid for by other people's programs.

Independence has practical value

An employee who tells the board that the program is not ready for a pre-BLA meeting is taking a career risk. A consultant saying the same thing is doing the job they were hired to do.

The same applies to due diligence, partnering conversations and internal disagreements about a control strategy. Internal reviewers have relationships to protect and histories with the decisions being examined. An outside technical voice with no stake in the org chart can say that a potency assay is not stability indicating, or that a comparability protocol is unlikely to survive review, without it landing as a critique of a colleague. They can also confirm to a board or an investor that the package is in good shape when it is. Both of those are useful.

When not to hire a consultant

When the work is execution rather than strategy. If you need methods run, hire a contract lab. Consultants are expensive per hour and should be pointed at decisions.

When you cannot act on the advice. A control strategy assessment does not get you much if there is no budget to implement the recommendations. Do the assessment when you can fund the response.

When the scope is genuinely full-time and permanent. If a program will need daily CMC leadership for the next four years, hire someone.

 Hire a consultant when the CMC problem in front of you is bigger than the CMC experience inside your company, which for most small biologics companies is most of the time between candidate selection and the BLA. Hire an FTE when the work is continuous, operational and permanent. Many companies need both, and the sequence usually runs consultant first and employee second, with the consultant helping define the role and often helping evaluate the candidates.

Takeaways

Point the engagement at decisions, not at a calendar. The highest value work is concentrated around specific inflection points: CQA and control strategy definition, process change and comparability, method validation strategy, pre-IND and pre-BLA preparation, and diligence.

Bring the outside view in before the decision, not after the deviation. Reviewing a comparability protocol costs a fraction of what it costs to explain a comparability failure.

If your manufacturing and testing are external, treat technical oversight as a function you must own. It is the one thing you cannot outsource to the people you are outsourcing to.

The right question is rarely whether you can afford a consultant. It is what the decision in front of you costs if you get it wrong, and in CMC that is usually measured in months of timeline rather than in fees.

If you are weighing one of those decisions right now, I am happy to talk it through.